Skip to content
10-Q

Quarterly Report

BioPlus Acquisition Corp.

0001193125-23-212329

← back to feed
Filed
Aug 14, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Stock Repurchased Q2 2023 · Jun 30, 2023 $104.71M
Stock Repurchased Q2 2023 · Jun 30, 2022 $67.5K
Operating Cash Flow Q2 2023 · Jun 30, 2023 −$1.19M
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$273.35K
Stockholders Equity Q2 2023 · Jun 30, 2023 −$16.58M
Stockholders Equity Q2 2023 · Mar 31, 2023 −$15.05M
Stockholders Equity Q2 2023 · Dec 31, 2022 −$14.78M
Stockholders Equity Q2 2023 · Jun 30, 2022 −$14.17M
Stockholders Equity Q2 2023 · Mar 31, 2022 −$13.86M
Stockholders Equity Q2 2023 · Dec 31, 2021 −$13.6M
Current Liabilities Q2 2023 · Jun 30, 2023 $1.98M
Current Liabilities Q2 2023 · Dec 31, 2022 $526.88K
Total Liabilities Q2 2023 · Jun 30, 2023 $16.78M
Total Liabilities Q2 2023 · Dec 31, 2022 $15.33M
Current Assets Q2 2023 · Jun 30, 2023 $196.84K
Current Assets Q2 2023 · Dec 31, 2022 $548.76K
Total Assets Q2 2023 · Jun 30, 2023 $138.63M
Total Assets Q2 2023 · Dec 31, 2022 $238.32M
Net Income Q2 2023 · Jun 30, 2023 $1.24M
Net Income Q2 2023 · Jun 30, 2023 $3.56M
Net Income Q2 2023 · Mar 31, 2023 $2.32M
Net Income Q2 2023 · Jun 30, 2022 $24.92K
Net Income Q2 2023 · Jun 30, 2022 −$236.9K
Net Income Q2 2023 · Mar 31, 2022 −$261.82K
Operating Income Q2 2023 · Jun 30, 2023 −$1.28M
Operating Income Q2 2023 · Jun 30, 2023 −$1.55M
Operating Income Q2 2023 · Jun 30, 2022 −$255.42K
Operating Income Q2 2023 · Jun 30, 2022 −$562.61K